

Byome Labs transforms skin diagnostics into cosmetics

Published on 01/13/2026 at 10:07 p.m. by Claire Lefèvre

Reading time: 8 minutes



Discover Byome Labs, the startup that is revolutionizing skin diagnostics in cosmetics with Byome Derma, after raising €3.6 million.

In Chartres and Clermont-Ferrand, Byome Labs is accelerating in a segment that is still unstructured in France: **the diagnosis of the skin microbiome** applied to cosmetics. Founded in 2023, the deeptech and medtech startup intends to transform microbiological analysis from a scientific promise to an operational tool at the point of sale. With Byome Derma, it is aiming for a new standard of personalization, supported by a **€3.6 million** fundraising in June 2025.

Byome Labs: a French deeptech positioned between cosmetics and diagnostics

Byome Labs defines itself as a French startup at the interface of biotech and medtech, specializing in the design of **skin microbiome test and diagnostic kits**. The company, founded in **2023**, has a dual presence, in **Chartres** and **Clermont-Ferrand**, which reflects an industrial and scientific logic: capacity to produce and industrialize, and proximity to research and health ecosystems.

Its purpose is clear: to analyse the micro-organisms naturally present on the skin, in order to extract a usable biological profile. The challenge goes beyond a simple laboratory exercise. The company wants to provide an answer to a problem well known to dermo-cosmetic players: inter-individual variability, often summarized as "dry skin" or "oily skin", while the biological reality is more subtle.

According to a publication by Forbes France, Byome Labs highlights its ability to **industrialize** kits dedicated to the skin microbiome, a decisive point in transforming a scientific innovation into a solution that can be sold on a large scale. In a market where POCs are multiplying but where production start-up remains a bottleneck, the industrial angle is a marker of differentiation.

Skin microbiome: what exactly are we talking about in a cosmetic setting ^

The skin microbiome refers to all the microorganisms present on the surface of the skin. In a cosmetics and dermo-cosmetics oriented approach, the interest lies in the possibility of **characterizing a "profile"** in order to adapt the choice of products. This positioning differs from strictly medical use: the objective here is not to establish a complete clinical diagnosis, but to make the information usable to guide a consumer towards a treatment that is more consistent with his or her biology.

Consumers and brands: personalization is becoming a matter of efficiency, not just marketing

The global cosmetics market is described as dynamic, and the demand for customization is growing. But personalization is no longer limited to brand speech. It is gradually being implemented in a logic of **perceived effectiveness** and the reduction of unsuccessful trials.

On the consumer side, the difficulty is recurrent: faced with wide ranges, sometimes similar promises and "surface" diagnoses, many struggle to select the really suitable products. The consequence is economic as well as reputational for brands: increased returns, customer disappointment, and erosion of trust in product innovation.

For manufacturers and distributors, two strategies emerge in the material supplied:

- **Designing inclusive products** that are meant to be suitable for the diversity of skin and microbiomes.
- **Guide clients** to the most appropriate care, based on a referral tool.

Byome Labs fits into this second option. His proposal aims to make the orientation more objective, with a "data then recommendation" reasoning. For a brand, the interest is twofold: to improve the experience at the point of sale and to strengthen the credibility of advice, without depending solely on a long consultation or rare expertise.

Why point-of-sale diagnostics can change the economics of a dermo-cosmetic range

A rapid on-site test has a potential impact on several operational indicators, without the need to announce undisclosed figures:

- **Reduction of "random" purchases** and abandonments after a first try.
- **Increase in the consistency** between the real need and the recommended product, thus improving satisfaction.
- **Better valuation of innovations** (active ingredients, routines, specialized ranges) thanks to a discourse based on measurement.

Byome Derma: industrialization financed by €3.6 million in June 2025

The most structuring financial milestone communicated in this area is the fundraising of **€3.6 million** in **June 2025**, allocated to the industrialization of the **Byome Derma** kit (amount recalled by publications cited in the raw content, including Le Point and Le Figaro).

From a business point of view, the choice of terms is important: industrialization is not a simple ramp-up. It involves the stabilization of a protocol, quality control, reproducibility, logistics, and adaptation to real environments (stores, institutes, dermo-cosmetics corners). In other words, the transition from technological proof to proof of performance.

Le Figaro (October 29, 2025) explicitly links this fundraising to the ambition to make skin diagnostics a **strategic tool** for cosmetic brands and dermatologists. For beauty players, the value lies as much in the customer experience as in the ability to formalize a recommendation, and therefore to structure partnerships with distribution networks.

Le Point (October 9, 2025) confirms the same amount and mentions the objective of industrializing the test as well as **international expansion**. From an economic point of view, internationalization is often the logical consequence of a "platformable" technology: once production is reliable, the growth lever becomes access to new markets, provided that the model is adapted to local frameworks.

Industrializing a biotech kit: what it means in practice ^

In a diagnostic product, industrialization means, in particular: securing supplies (consumables, components), standardizing procedures, guaranteeing the **robustness** of the test under various conditions of use, and setting up traceability compatible with the requirements of professional customers. Even without detailing unmentioned standards, the central idea remains the same: a useful test is not only "possible", it must be **repeatable** and **deployable**.

A non-invasive device, an AI interpretation solution: the operational promise in stores

Byome Derma is presented as a kit designed for the cosmetics industry, with a personalized recommendation purpose. The technical principle described is based on a **non-invasive sample** via a swab and antigenic strips. The analysis is announced as fast and achievable at the point of sale, which changes the nature of the product: we are not talking about a remote service requiring a long lead time, but a decision-making tool integrated into a retail experience.

The software brick is central. The material indicates that an **AI** developed with dermatologists interprets the data. The important point, on the business side, is not to promise algorithmic "magic", but to transform biological signals into a comprehensible and actionable recommendation. The value lies in the interpretation and in the ability to integrate it into product catalogues.

This positioning also raises a question of innovation governance: a recommendation AI, backed by a biological analysis, reinforces the need for clear internal rules on data quality, model documentation, and the way in which the recommendation is presented to the end consumer. At this stage, the material provided does not detail these elements, so it is important to remain factual: the AI is announced as co-developed with dermatologists and used to interpret the results.

Dermo-cosmetics: why "biological" analysis attracts brands

Dermo-cosmetic brands often seek to reconcile two imperatives: reassuring (safety, tolerance) and demonstrating effectiveness. A tool like Byome Derma fits into this logic because it:

- highlights a **measure** rather than a simple self-assessment,
- allows a personalized recommendation without imposing a long consultation,
- reinforces the coherence between scientific discourse, advice and product.

Awards, CES 2026: commercial traction is also based on credibility

External recognition is part of the "trust capital" of a startup that sells a tool with a scientific component. In this area, Byome Labs says it has won the **2025 Cosmetics Awards** and the **2025 Puy-de-Dôme Business Trophy**. These distinctions do not replace market validation, but they help reduce some of the perceived risk by industry partners or distribution networks.

Another milestone: the selection for the **CES in Las Vegas in January 2026**. The company is to present Byome Derma, in a logic of technological showcase. On the business side, the interest of CES is rarely the immediate signature, but the access to structuring discussions: distributors, international brands, technology partners, and North American ecosystems.

The material associates this step with an opening to the **American** and **Canadian** markets, then with a long-term strategy towards Asia, citing **Japan** and **South Korea**, identified as references in retail and cosmetics. No detailed timeline is provided beyond this general direction, so it is prudent to retain the strategic intent without extrapolating operational steps.

CES: what a selection means for a French diagnostics startup ^

Being selected for the CES in Las Vegas provides a solution for a variety of audiences: retail innovation, health tech, beauty, data. For a startup, the benefit is often indirect: acceleration of contacts, international visibility, and a signal sent to potential partners. This does not prejudice commercial success, but can facilitate access to faster decision cycles among global players.

Plant announced in 2026, lifted in June 2026: industrial progress as a financial challenge

Byome Labs plans to open a **new production facility in 2026**. The message is consistent with the industrialization objective: to produce more, better and in a more integrated way, while supporting **co-developments** with partners. At this stage, the matter does not specify the location, capacity or number of associated jobs.

On the financial front, the company has announced a **€5 million fundraising** round planned for **June 2026**. This trajectory illustrates a classic pattern in deeptech: a first round to pass the initial industrialization phase, then additional financing to consolidate the production system and support expansion, while continuing **R&D**.

The notable point is the claimed broadening of research priorities, with a greater emphasis on the medical field. For a biotech, this implies a change in the level of requirements in terms of validation, partners and regulatory framework. The subject does not detail the exact regulatory status of future devices, so it is necessary to limit ourselves to the intention: to push expertise towards medical uses, without prejudging the necessary steps.

In the French ecosystem, this dynamic is part of a period in which the public authorities are prioritizing innovation in health and prevention. Initiatives related to **France 2030** and the **French Tech 2030** programme are mentioned in the subject (government press release of 3 December 2025 for the Prevention Challenge, and information published on 7 November 2025 on the La French Tech website).

Byome Labs is not presented as a winner. On the other hand, its position on prevention and objective measurement is aligned with this general orientation.

The two value horizons: retail cosmetics and medical uses

1. **Short-term:** deployment of a point-of-sale test to improve advice and support the personalization of routines.
2. **Longer term:** development of devices for dermatologists and the pharmaceutical industry, with reinforced validation requirements.

From the skin microbiome to the scalp, then to the vaginal and oral: a scientific roadmap to watch

Beyond the skin, Byome Labs is considering extending its analyses to the **scalp**, with an application mentioned on products such as anti-dandruff shampoos. The economic interest is obvious: haircare is a distinct market, with its own problems and a recurring need for segmentation (dandruff, sensitivity, imbalances).

Later in the roadmap, the material mentions potential tests on the **vaginal** and **oral** microbiome. This perspective opens up a wide field, but it also potentially implies validation constraints and more sensitive uses. No timetable is communicated for these axes beyond the "long-term" intention.

Finally, a medical application is explicitly mentioned: devices for dermatologists and the pharmaceutical industry to quickly detect and diagnose pathologies such as **eczema**, with a project planned for **2027**. While cosmetics often finance the early phases of deployment of certain measurement technologies, the switch to the medical sector is changing the nature of the risk and the sales cycle. For the company, this means building a coherent portfolio: maintaining a retail model that generates traction, while investing in longer projects.

Between industrialization, validation and internationalization, Byome Labs is on a trajectory where scientific credibility must remain at the level of commercial execution.